Nav: Home

Increasing rates of medical male circumcision, female ART coverage linked with lower rates of HIV

July 12, 2016

In a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue, Xiangrong Kong, Ph.D., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined whether increasing community medical male circumcision and antiretroviral therapy (ART) coverage was associated with reduced community HIV incidence in Uganda.

Randomized trials have shown that medical male circumcision (MMC) reduces male HIV acquisition by 50 percent to 60 percent, and that early initiation of ART reduces HIV transmission by more than 90 percent in HIV-discordant couples. There are limited data on the population-level effect of scale-up of these interventions in sub-Saharan Africa. Such evaluation is important for planning and resource allocation.

Using data from population-based surveys conducted from 1999 through 2013 in 45 rural Rakai, Uganda communities, community-level ART and MMC coverage, sociodemographics, sexual behaviors, and HIV prevalence and incidence were estimated in 3 periods: prior to the availability of ART and MMC (1999-2004), during early availability of ART and MMC (2004-2007), and during mature program scale-up (2007-2013).

From 1999 through 2013, 44,688 persons participated in 1 or more surveys. Median community MMC coverage increased from 19 percent to 39 percent, and median community ART coverage rose from 0 percent to 21 percent in males and from 0 percent to 26 percent in females. Median community HIV incidence declined from 1.25 to 0.84 per 100 person-years in males, and from 1.25 to 0.99 per 100 person-years in females. Analysis indicated that increasing community-level coverage of MMC was associated with significant reductions in male community HIV incidence. For example, in communities with MMC more than 40 percent, male HIV incidence was 0.66 per 100 person-years lower than in communities with MMC coverage 10 percent or less.

"This difference is substantial to these communities and suggests that increasing MMC coverage more than 40 percent could reduce male incidence by approximately 39 percent at a population-level. This is comparable with the estimated reduction in individual HIV acquisition risk associated with comparable ART coverage in South Africa," the authors write.

"Because MMC provides direct protection against male HIV acquisition, this association is plausible and consistent with the estimated associations of increasing MMC coverage with male HIV prevalence from cross-sectional analyses in South Africa. Female community HIV incidence was not significantly associated with male MMC coverage during the study period, consistent with mathematical models suggesting that the HIV prevention benefits of MMC to women accrue over longer periods."

The researchers write that if similar associations are found elsewhere regarding increasing community MMC and female ART coverage, this would support further scale-up of MMC and ART for HIV prevention in sub-Saharan Africa.
-end-
(doi:10.1001/jama.2016.7292; the study is available pre-embargo to the media at the For the Media website)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact Xiangrong Kong, Ph.D., email Stephanie Desmon (sdesmon1@jhu.edu) or Barbara Benham (bbenham1@jhu.edu).

To place an electronic embedded link to this study in your story This link for the study will be live at the embargo time: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.7292

The JAMA Network Journals

Related Hiv Articles:

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
HIV RNA expression inhibitors may restore immune function in HIV-infected individuals
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity.
HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world.
State-of-the-art HIV drug could curb HIV transmission, improve survival in India
An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 percent with minimal impact on the country's HIV/AIDS budget.
More Hiv News and Hiv Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.